Breaking news from the ACC: Vytorin/Zetia gets panned - shows no benefit on the primary endpoint, though effective in reducing some markers. Doctors now wary and skeptical. Merck and Schering-Plough …
Pharma News 11_9
A huge week for news, especially on the cardiovascular front: Prasugrel, the Lilly/Daiichi-Sankyo blood thinner, was the biggest headline grabber. This potential blockbuster came in with mixed …